The RAGE-knocked down (KD) breast cancer and inhibitors against PI3K and AKT were applied to investigate that RAGE-PI3K/AKT signaling pathway activated by HMGB1 could regulate aggressive breast cancer cell properties and PD-L1 expression leading to acquired resistance to breast cancer treatment. Here, AKT1 is linked to breast carcinoma.